Coronavirus

Urtica dioica agglutinin (UDA) is a small plant monomeric lectin, 8.7 kDa in size, with an N-acetylglucosamine specificity that inhibits viruses from Nidovirales in vitro. In the current study, we first examined the efficacy of UDA on the replication of different SARS-CoV strains in Vero 76 cells. U …

It’s been over six weeks since Iowa dropped all state-level COVID restrictions, and surprise, surprise, hospitalized patients are down 54 percent. But if you try to Google this information, all you will see is death, dying, and it must be the end of the world because of COVID, which miraculously seems to be a cure... View Article

Compromised lung function is a feature of both infection driven and non-infective pathologies. Viral infections—including the current pandemic strain SARS-CoV-2—that affect lung function can cause both acute and long-term chronic damage. SARS-CoV-2 infection suppresses innate immunity and promotes an inflammatory response. Targeting these aspects of SARS-CoV-2 is important as the pandemic affects greater proportions of the population. In clinical and animal studies, fucoidans have been shown to increase innate immunity and decrease inflammation. In addition, dietary fucoidan has been shown to attenuate pulmonary damage in a model of acute viral infection. Direct inhibition of SARS-CoV-2 in vitro has been described, but is not universal. This short review summarizes the current research on fucoidan with regard to viral lung infections and lung damage.

‘Doctors say CDC should warn people the side effects from Covid vaccine shots won’t be a walk in the park.’ Be warned to expect severe reactions to the new COVID vaccines. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research, told reporters he was not certain what is causing all the vaccine reactions. But... View Article

Nitric oxide (NO) is an important signaling molecule between cells which has been shown to have an inhibitory effect on some virus infections. The purpose of this study was to examine whether NO inhibits the replication cycle of the severe acute respiratory ...

We describe the antiviral activity of plant lectins with specificity for different glycan structures against the severe acute respiratory syndrome cor…

Countries worldwide have confirmed a staggering number of COVID-19 cases, and it is now clear that no country is immune to the SARS-CoV-2 infection. Resource-poor countries with weaker health systems are struggling with epidemics of their own and are now in a more uncertain situation with this rapid …

Nitric oxide (NO) represents a key signaling molecule in multiple regulatory pathways underlying vascular, metabolic, immune, and neurological function across animal phyla. Our brief critical discussion is focused on the multiple roles of the NO signaling pathways in the maintenance of basal physiol …

Objectives To investigate the potential efficacy of Acacia Senegal extract Gum Arabic (GA) supplementation as immunomodulatory and anti-inflammatory dietary intervention among newly diagnosed COVID 19 Sudanese patients. To study the effect of GA on the level of cytokines, TNFα, IL8, IL6 IL10, CRP and the viral load. Secondary outcomes will be the effect of GA oral intake on mortality rate and days of hospital admission. Trial design Quadruple blind, randomized placebo-controlled clinical trial Phase II & III. Prospective, two-arm, parallel-group, randomised (1:1 allocation ratio) superiority trial of oral GA among seropositive COVID-19 patients. Participants Inclusion criteria: COVID-19 infected (newly diagnosed) as proved by real-time PCR within 72 hours of PCR. Age 8-90 years Both genders Exclusion criteria: Intubated patients on parenteral treatment Allergy to Gum Arabic The study will be conducted in COVID Isolation Centres and Soba University Hospital Khartoum State Sudan. Intervention and comparator Experimental: Intervention Group This arm will receive 100% natural Gum Arabic provided in a powder form in 30-grams-dose once daily for four weeks Placebo Comparator: Control group: This group will be provided with pectin powder provided as one-gram-dose once daily for four weeks Both GA and placebo will be in addition to standard care treatment based on local clinical guidelines. Main outcomes Mean change from baseline score of Immune Response to end of the trial. Changes of the level of Tumor Necrosis Factor (TNFα), interleukin IL8, IL6, and IL10 from the baseline values (Four weeks from the start of randomization). Mortality rate: The percentage of deaths among COVID 19 patients received Gum Arabic compared to placebo (Four weeks from the start of randomization]). Randomisation Randomization (1:1 allocation ratio) and will be conducted using a sequence of computer-generated random numbers by an independent individual. Each participating centre will be assigned a special code generated by the computer. The randomization will be kept by the PI and a research assistant. Blinding (masking) Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Numbers to be randomised (sample size) 110 eligible patients will be randomly assigned to either GA (n=55) or placebo (n=55) groups. Trial Status Protocol Version no 2, 30th June 2020. Recruitment will start on 15th September 2020. The intended completion date is 15th January 2021. Trial registration ClinicalTrials.gov Identifier: NCT04381871 . Date of trial registration: 11 May 2020. Full protocol The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.

Nitric oxide (NO) is a free radical playing an important pathophysiological role in cardiovascular and immune systems. Recent studies reported that NO levels were significantly lower in patients with COVID-19, which was suggested to be closely related to vascular dysfunction and immune inflammation …

Click here to subscribe - https://www.glutenfreesociety.org/wxrn Quercetin is a bioflavonoid. It's a plant based product or chemical that has antiinflammatory properties on that enzyme. Quercetin can have a very nice antiinflammatory effect if you're taking it prophylactically. There's actually research studies that show quercetin has antiviral properties,and that quercetin actually can reduce the risk of developing upper airway diseases, upper respiratory tract infections and things of that nature. Quercetin also blocks the cycle oxygen ACE enzyme. That's why a lot of scientists are focusing in on quercitin as a potential. I wouldn't recommend quercitin to block the COX enzyme to reduce a fever because it doesn't work quite that way. Quercitin is not going to have that acute fever reducing capacity, but it is going to have that that overall reduction in overall inflammatory capacity. Then why do we want to know about this as it relates to any virus? Well, the research shows that quercetin through its effect on inflammation, can inhibit viral replication in multiple different areas. It's been very, very powerful as a nutrient in regards to immune function. So a lot of you have asked me, because vitamin C is very scarce right now, what can I use if I want to support my immune system right now? What can I use instead of vitamin C? I just can't find any vitamin C. Well, one of the things you can use is quercetin. Quercetin is very, very good at a lot of the things that vitamin C is good at. And because of its antiviral properties, it's actually been studied to be antiviral against the rhinovirus, against influenza, against the hepatitis virus, against Ebola virus. So there are a number of research studies that show that course it's in has very potent antiviral effects. Coronavirus resource page: https://www.glutenfreesociety.org/viral-outbreaks ** The products, supplements, vitamins, minerals, herbs, etc mentioned in these videos and article are not intended to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. There currently are no vaccines, pills, potions, lotions, lozenges or other prescription or over the-counter products available to treat or cure coronavirus disease 2019 (COVID-19) The information in these videos, and article is provided for educational purposes and should not be construed as medical advice. If you are seeking medical advice in regards to COVID-19 please visit the WHO website: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen

Norovirus is the leading cause of nonbacterial foodborne disease outbreaks. Human noroviruses (HuNoVs) bind to histo-blood group antigens as the host receptor for infection. In this study, the inhibitory effects of fucoidans from brown algae, Laminaria japonica (LJ), Undaria pinnatifida and Undaria pinnatifida sporophyll, were evaluated against murine norovirus (MNoV), feline calicivirus (FCV) and HuNoV. Pretreatment of MNoV or FCV with the fucoidans at 1 mg/mL showed high antiviral activities, with 1.1 average log reductions of viral titers in plaque assays. They also showed significant inhibition on the binding of the P domains of HuNoV GII.4 and GII.17 to A- or O-type saliva and the LJ fucoidan was the most effective, reaching 54–72% inhibition at 1 mg/mL. In STAT1−/− mice infected with MNoV, oral administration of the LJ fucoidan, composed of mainly sulfated fucose and minor amounts of glucose and galactose, improved the survival rates of mice and significantly reduced the viral titers in their feces. Overall, these results provide the LJ fucoidan can be used to reduce NoV outbreaks.

Watch Donate To Ican Coronavirus LIVE FROM ‘EVENT 2021’ IN DALLAS, TX MEDIA CAUGHT LYING ABOUT LONDON MEGA-RALLY TROUBLING SCIENCE EMERGING ON SPIKE PROTEIN 117 EMPLOYEES SUE HOSPITAL OVER VACCINE MANDATE Del is back! TOMORROW on The HighWire, June 3rd, 2021! HEART INFLAMMATION IN YOUTH RECENTLY VAXXED OSHA TURNS BLIND EYE TO VACCINE INJURY CDC… Read More »Watch

My work to help people is to educate them to use ICU and emergency room natural medicines to make them stronger. It surprises people to discover that substances like magnesium, sodium bicarbonate, iodine, selenium, and even vitamin C and D, when used at high dosages, are employed by doctors to save peoples’ lives in critical... View Article

Importance No therapy to date has been shown to improve survival for patients infected with SARS-CoV-2. Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in vitro but clinical response has not been previously evaluated. Objective To determine whether Ivermectin is associated with lower mortality rate in patients hospitalized with COVID-19. Design and Setting Retrospective cohort study of consecutive patients hospitalized at four Broward Health hospitals in South Florida with confirmed SARS-CoV-2. Enrollment dates were March 15, 2020 through May 11, 2020. Follow up data for all outcomes was May 19, 2020. Participants 280 patients with confirmed SARS-CoV-2 infection (mean age 59.6 years [standard deviation 17.9], 45.4% female), of whom 173 were treated with ivermectin and 107 were usual care were reviewed. 27 identified patients were not reviewed due to multiple admissions, lack of confirmed COVID results during hospitalization, age less than 18, pregnancy, or incarceration. Exposure Patients were categorized into two treatment groups based on whether they received at least one dose of ivermectin at any time during the hospitalization. Treatment decisions were at the discretion of the treating physicians. Severe pulmonary involvement at study entry was characterized as need for either FiO2 ≥50%, or noninvasive or invasive mechanical ventilation. Main Outcomes and Measures The primary outcome was all-cause in-hospital mortality. Secondary outcomes included subgroup mortality in patients with severe pulmonary involvement and extubation rates for patients requiring invasive ventilation. Results Univariate analysis showed lower mortality in the ivermectin group (15.0% versus 25.2%, OR 0.52, 95% CI 0.29-0.96, P=.03). Mortality was also lower among 75 patients with severe pulmonary disease treated with ivermectin (38.8% vs 80.7%, OR 0.15, CI 0.05-0.47, P=.001), but there was no significant difference in successful extubation rates (36.1% vs 15.4%, OR 3.11 (0.88-11.00), p=.07). After adjustment for between-group differences and mortality risks, the mortality difference remained significant for the entire cohort (OR 0.27, CI 0.09-0.85, p=.03; HR 0.37, CI 0.19-0.71, p=.03). Conclusions and Relevance Ivermectin was associated with lower mortality during treatment of COVID-19, especially in patients who required higher inspired oxygen or ventilatory support. These findings should be further evaluated with randomized controlled trials. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial n/a ### Funding Statement No funding. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Study was approved by the Broward Health IRB All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes De-dentified data is available upon request and approval by the Broward Health IRB.

People are dying, but what are they dying from? Is it an all-powerful virus that is doing hundreds of thousands of people in, or is it medical ignorance and medical malpractice? Ignorance is deadly in medicine and is usually sourced in arrogance and pharmaceutical greed and power, which is in full view with the American... View Article

Importance No therapy to date has been shown to improve survival for patients infected with SARS-CoV-2. Ivermectin has been shown to inhibit the replication of SARS-CoV-2 in vitro but clinical response has not been previously evaluated. Objective To determine whether Ivermectin is associated with lower mortality rate in patients hospitalized with COVID-19. Design and Setting Retrospective cohort study of consecutive patients hospitalized at four Broward Health hospitals in South Florida with confirmed SARS-CoV-2. Enrollment dates were March 15, 2020 through May 11, 2020. Follow up data for all outcomes was May 19, 2020. Participants 280 patients with confirmed SARS-CoV-2 infection (mean age 59.6 years [standard deviation 17.9], 45.4% female), of whom 173 were treated with ivermectin and 107 were usual care were reviewed. 27 identified patients were not reviewed due to multiple admissions, lack of confirmed COVID results during hospitalization, age less than 18, pregnancy, or incarceration. Exposure Patients were categorized into two treatment groups based on whether they received at least one dose of ivermectin at any time during the hospitalization. Treatment decisions were at the discretion of the treating physicians. Severe pulmonary involvement at study entry was characterized as need for either FiO2 ≥50%, or noninvasive or invasive mechanical ventilation. Main Outcomes and Measures The primary outcome was all-cause in-hospital mortality. Secondary outcomes included subgroup mortality in patients with severe pulmonary involvement and extubation rates for patients requiring invasive ventilation. Results Univariate analysis showed lower mortality in the ivermectin group (15.0% versus 25.2%, OR 0.52, 95% CI 0.29-0.96, P=.03). Mortality was also lower among 75 patients with severe pulmonary disease treated with ivermectin (38.8% vs 80.7%, OR 0.15, CI 0.05-0.47, P=.001), but there was no significant difference in successful extubation rates (36.1% vs 15.4%, OR 3.11 (0.88-11.00), p=.07). After adjustment for between-group differences and mortality risks, the mortality difference remained significant for the entire cohort (OR 0.27, CI 0.09-0.85, p=.03; HR 0.37, CI 0.19-0.71, p=.03). Conclusions and Relevance Ivermectin was associated with lower mortality during treatment of COVID-19, especially in patients who required higher inspired oxygen or ventilatory support. These findings should be further evaluated with randomized controlled trials. ### Competing Interest Statement The authors have declared no competing interest. ### Clinical Trial n/a ### Funding Statement No funding. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Study was approved by the Broward Health IRB All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes De-dentified data is available upon request and approval by the Broward Health IRB.